Bexagliflozin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for bexagliflozin and what is the scope of patent protection?
Bexagliflozin
is the generic ingredient in one branded drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Bexagliflozin has seventy-one patent family members in thirty-two countries.
Two suppliers are listed for this compound.
Summary for bexagliflozin
International Patents: | 71 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Clinical Trials: | 16 |
Patent Applications: | 116 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for bexagliflozin |
What excipients (inactive ingredients) are in bexagliflozin? | bexagliflozin excipients list |
DailyMed Link: | bexagliflozin at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bexagliflozin
Generic Entry Date for bexagliflozin*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for bexagliflozin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Theracos | Phase 2/Phase 3 |
Theracos | Phase 1 |
Theracos | Phase 3 |
Pharmacology for bexagliflozin
Drug Class | Sodium-Glucose Cotransporter 2 Inhibitor |
Mechanism of Action | Sodium-Glucose Transporter 2 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for bexagliflozin
US Patents and Regulatory Information for bexagliflozin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for bexagliflozin
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Argentina | 110796 | DERIVADOS DE BENCILBENCENO | ⤷ Sign Up |
Brazil | PI0815708 | COMPOSTO, ÉSTER DE PRÓ-DROGA, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA TRATAR UMA DOENÇA OU CONDIÇÃO. | ⤷ Sign Up |
Croatia | P20180127 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.